<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618915</url>
  </required_header>
  <id_info>
    <org_study_id>101HEMB01</org_study_id>
    <nct_id>NCT02618915</nct_id>
  </id_info>
  <brief_title>Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B</brief_title>
  <official_title>Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dimension Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dimension Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/2, open-label, dose-finding safety study of single ascending doses of DTX101 in
      adult males with moderate/severe to severe hemophilia B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemophilia B is an X-linked recessive genetic bleeding disorder caused by mutations in the
      factor IX (FIX) gene. FIX is produced in the liver and is critical for fibrin clot formation.
      Hemophilia B is characterized by frequent, spontaneous internal bleeding that can lead to
      chronic arthropathy (joint damage), intracranial hemorrhage, and even death. In patients with
      moderate/severe to severe hemophilia B, the majority of bleeding episodes occur in the joints
      and, if not treated, lead to debilitating damage and a decreased quality of life.

      This study will evaluate the safety and efficacy of the adeno-associated virus (AAV) to
      deliver human factor IX (hFIX) gene, the healthy gene necessary to make FIX, to the liver
      where FIX is normally produced. This study will determine if AAVrh10 can produce clinically
      meaningful FIX levels in patients with moderately/severe or severe hemophilia B.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of treatment-related adverse events by dosing group</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in FIX activity level</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Bleeding Episodes requiring recombinant FIX infusion</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.6 x 10^12 GC/kg DTX101(AAVrh10FIX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 x 10^12 GC/kg DTX101 (AAVrh10FIX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 x 10^12 GC/kg DTX101 (AAVrh10FIX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 x 10^13 GC/kg DTX101 (AAVrh10FIX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAVrh10FIX</intervention_name>
    <description>non-replicating recombinant AAVrh10 encoding human FIX (hFIX)</description>
    <arm_group_label>Dose 1</arm_group_label>
    <other_name>DTX101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAVrh10FIX</intervention_name>
    <description>non-replicating recombinant AAVrh10 encoding human FIX (hFIX)</description>
    <arm_group_label>Dose 2</arm_group_label>
    <other_name>DTX101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAVrh10FIX</intervention_name>
    <description>non-replicating recombinant AAVrh10 encoding human FIX (hFIX)</description>
    <arm_group_label>Dose 3</arm_group_label>
    <other_name>DTX101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAVrh10FIX</intervention_name>
    <description>non-replicating recombinant AAVrh10 encoding human FIX (hFIX)</description>
    <arm_group_label>Dose 4</arm_group_label>
    <other_name>DTX101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male ≥18 years of age.

          2. Moderate/severe or severe hemophilia B (baseline FIX activity ≤2% of normal or
             documented history of FIX activity ≤2%).

          3. At least 3 bleeding episodes per year that require on-demand treatment with FIX OR are
             treated with a prophylactic regimen of FIX.

          4. At least 100 days exposure history to FIX.

          5. No documented history of inhibitors (neutralizing antibodies) to exogenous FIX.

          6. No known allergic reaction to exogenous FIX or any component of DTX101.

          7. Willing to stop prophylactic treatment with recombinant FIX at specified time points
             during the study.

        Exclusion Criteria:

          1. History of significant liver disease (ie;portal hypertension).

          2. Significant hepatic inflammation or cirrhosis.

          3. Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

          4. History of human immunodeficiency virus (HIV) infection AND any of the following: CD4+
             cell count &lt;350 cells/mm3, change in antiretroviral therapy regimen within 6 months
             prior to Day 0, or plasma viral load &gt;200 copies/mL, on 2 separate occasions, as
             measured by PCR.

          5. Anti-AAVrh10 neutralizing antibody titer &gt;1:5.

          6. Participation (current or previous) in another gene therapy study.

          7. Participation in another investigational medicine study within 3 months before
             screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Poma, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dimension Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Institute for Children</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital and Health Systems, Michigan Clinical Research Unit</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Hemostasis-Thrombosis Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment for Hematological Disease</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire Hospital, Haemophilia, Haemostasis and Thrombosis Centre</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>Hemophilia B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

